Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/menveo-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Menveo (Meningococcal groups A, C, Y, W-135 oligosaccharide diphtheria CRM197 conjugate vaccine) is Novartis’ tetravalent conjugate vaccine licensed in the US, EU, Australia, and Brazil to protect against four serogroups of N. meningitidis (A, C, Y, W-135) that cause meningococcal disease in children, adolescents, and adults. Approved in 2010 for all markets in this report, Menveo was the second tetravalent conjugate vaccine to enter the market in US and Australia and the first to enter the 5EU markets.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menveo including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menveo for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menveo performance

Obtain sales forecast for Menveo from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 16

3.3 Prognosis 17

4 Disease Management 18

4.1 Meningococcal Immunization Policy 19

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171848

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074